Navigation Links
Combination therapy reduced HER2-positive breast cancers
Date:12/10/2010

SAN ANTONIO A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

  • U.S. and Canada: (888) 282-7404
  • International: (706) 679-5207
  • Access Code: 25346432

Lead researcher Jos Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone.

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease," said Baselga, who is also a founding editor-in-chief of the AACR's newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

"It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting," said Baselga.

At the symposium, Baselga presented the primary outcome of tu
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
2. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
3. Grape news: New treatment combination safe alternative to sulfur dioxide
4. Study: Grass, fungus combination affects ecology
5. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
6. Diabetes drug kills cancer stem cells in combination treatment in mice
7. Old stain in a new combination
8. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
9. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
10. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... volcanic eruptions shows an unexpected connection with jet engines. ... Diego speeded up the recorded sounds from two volcanoes ... engines. These new research findings provide scientists with a ... eruptions. Infrasound is sound that is lower in frequency ...
... Researchers have identified a gene that controls the rapid ... all blood cell types -- a discovery that could ... leukemia and other blood cancers, in which blood cells ... the mechanisms of this gene, the scientists uncovered evidence ...
... April 8, 2009 -- Investigators at Burnham Institute for ... the total protein complement (proteome) in Schizosaccharomyces pombe ... Brill, Khatereh Motamedchaboki, Ph.D. and lead investigator Dieter Wolf, ... proteins in the organism, using an array of sophisticated ...
Cached Biology News:Study compares sound from exploding volcanoes with jet engines 2Scientists identify key gene that protects against leukemia 2Scientists identify key gene that protects against leukemia 3
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Cell Through In Vivo ... Imaging-, ... ) today introduced Bioware(R) Ultra cell lines,a range of ultra bright light ... cell lines are,10 to 100 times brighter than cell lines created using ...
... Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) announced that ... Nemours Center for Childhood Cancer Research entitled,"Radiation in ... at the American Association for Cancer Research (AACR),Annual ... Diego, California from,April 12-16, 2008., "The combination ...
... Sign Manufacturing and Distribution Agreement, GURGAON, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned subsidiary ... it has reached several,agreements with AstraZeneca. Two ... third agreement pertains to Omeprazole 40mg,tablets, and ...
Cached Biology Technology:Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Procollagen type I C-terminal propeptide (human, PICP)...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
Biology Products: